Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-02-06

AUTHORS

Nahoko Hatsumi, Shuichi Miyawaki, Takahiro Yamauchi, Akihiro Takeshita, Norio Komatsu, Noriko Usui, Yukihiro Arai, Fumihiro Ishida, Takeshi Morii, Yasuhiko Kano, Michinori Ogura, Shinichiro Machida, Kazuhiro Nishii, Sumihisa Honda, Kazunori Ohnishi, Tomoki Naoe,

ABSTRACT

Given the poor prognosis of patients with relapsed/refractory acute myeloid leukemia (AML), better therapy is needed. Fludarabine enhances the efficacy of Ara-C (cytarabine) by increasing intracellular Ara-C-triphosphate. The FLAG (fludarabine, high-dose Ara-C, supported with granulocyte colony-stimulating factor) regimen has been tested for use in AML patients by other investigators. In the phase II study reported here, we evaluated the efficacy and toxicity of FLAGM therapy (FLAG with mitoxantrone), further intensified by adding mitoxantrone, based on the results of a phase I study by our group. The major endpoints were complete remission (CR) rate and early death. From June 2004 to February 2008, 41 patients (median age 52 years; range 18–64 years) were enrolled. Thirty (73% 95% CI 58–84%) patients achieved CR, which met the primary endpoint; there was a single case of early death from pneumonia. Two-year overall survival was 39.4% (95% CI 25.2–55.6%). Of those who achieved CR, 27 underwent allogeneic stem cell transplantation (SCT), and 12 SCT recipients showed long-term survival. Grade 3/4 non-hematological adverse events included infection (59%), nausea/vomiting (15%), diarrhea (7%), and elevated liver enzymes (7%). In conclusion, FLAGM is an effective and safe salvage therapy for patients with relapsed/refractory AML, and facilitated SCT for a large proportion of patients. More... »

PAGES

418-425

Journal

TITLE

International Journal of Hematology

ISSUE

4

VOLUME

109

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-019-02606-0

DOI

http://dx.doi.org/10.1007/s12185-019-02606-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111933579

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30725360


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytarabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Granulocyte Colony-Stimulating Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitoxantrone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vidarabine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416616.2", 
          "name": [
            "Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hatsumi", 
        "givenName": "Nahoko", 
        "id": "sg:person.0731776361.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731776361.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka Toshima-ku, 170-8476, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410806.b", 
          "name": [
            "Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan", 
            "Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka Toshima-ku, 170-8476, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyawaki", 
        "givenName": "Shuichi", 
        "id": "sg:person.0575627640.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575627640.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan", 
          "id": "http://www.grid.ac/institutes/grid.163577.1", 
          "name": [
            "First Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamauchi", 
        "givenName": "Takahiro", 
        "id": "sg:person.012076005472.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012076005472.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.505613.4", 
          "name": [
            "Department of Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takeshita", 
        "givenName": "Akihiro", 
        "id": "sg:person.01214531143.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214531143.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Jichi Medical University, Shimotsuke, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410804.9", 
          "name": [
            "Division of Hematology, Jichi Medical University, Shimotsuke, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komatsu", 
        "givenName": "Norio", 
        "id": "sg:person.0763374015.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763374015.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Usui", 
        "givenName": "Noriko", 
        "id": "sg:person.01114721672.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114721672.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Dokkyo University School of Medicine, Mibu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412039.d", 
          "name": [
            "Department of Hematology, Dokkyo University School of Medicine, Mibu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arai", 
        "givenName": "Yukihiro", 
        "id": "sg:person.0716044066.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716044066.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.263518.b", 
          "name": [
            "Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishida", 
        "givenName": "Fumihiro", 
        "id": "sg:person.0601706771.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601706771.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Second Department of Internal Medicine, Nara Medical University, Nara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410814.8", 
          "name": [
            "The Second Department of Internal Medicine, Nara Medical University, Nara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morii", 
        "givenName": "Takeshi", 
        "id": "sg:person.01103067640.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103067640.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Tochigi Cancer Center, Utsunomiya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.420115.3", 
          "name": [
            "Division of Hematology, Tochigi Cancer Center, Utsunomiya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kano", 
        "givenName": "Yasuhiko", 
        "id": "sg:person.0603027536.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603027536.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415067.1", 
          "name": [
            "Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan", 
            "Department of Hematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ogura", 
        "givenName": "Michinori", 
        "id": "sg:person.01173414200.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173414200.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.265061.6", 
          "name": [
            "Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Machida", 
        "givenName": "Shinichiro", 
        "id": "sg:person.01364761132.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364761132.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.260026.0", 
          "name": [
            "Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishii", 
        "givenName": "Kazuhiro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.174567.6", 
          "name": [
            "Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Honda", 
        "givenName": "Sumihisa", 
        "id": "sg:person.016200371441.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016200371441.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology Center, Hamamatsu University School of Medicine, Hamamatsu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.505613.4", 
          "name": [
            "Oncology Center, Hamamatsu University School of Medicine, Hamamatsu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohnishi", 
        "givenName": "Kazunori", 
        "id": "sg:person.01343053337.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343053337.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.27476.30", 
          "name": [
            "Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Naoe", 
        "givenName": "Tomoki", 
        "id": "sg:person.0617447237.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617447237.02"
        ], 
        "type": "Person"
      }, 
      {}
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2401568", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036106851", 
          "https://doi.org/10.1038/sj.leu.2401568"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-003-0624-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075273463", 
          "https://doi.org/10.1007/s00277-003-0624-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2401406", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023213497", 
          "https://doi.org/10.1038/sj.leu.2401406"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002770050541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050548097", 
          "https://doi.org/10.1007/s002770050541"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1532/ijh97.07072", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015720903", 
          "https://doi.org/10.1532/ijh97.07072"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-02-06", 
    "datePublishedReg": "2019-02-06", 
    "description": "Given the poor prognosis of patients with relapsed/refractory acute myeloid leukemia (AML), better therapy is needed. Fludarabine enhances the efficacy of Ara-C (cytarabine) by increasing intracellular Ara-C-triphosphate. The FLAG (fludarabine, high-dose Ara-C, supported with granulocyte colony-stimulating factor) regimen has been tested for use in AML patients by other investigators. In the phase II study reported here, we evaluated the efficacy and toxicity of FLAGM therapy (FLAG with mitoxantrone), further intensified by adding mitoxantrone, based on the results of a phase I study by our group. The major endpoints were complete remission (CR) rate and early death. From June 2004 to February 2008, 41 patients (median age 52 years; range 18\u201364\u00a0years) were enrolled. Thirty (73% 95% CI 58\u201384%) patients achieved CR, which met the primary endpoint; there was a single case of early death from pneumonia. Two-year overall survival was 39.4% (95% CI 25.2\u201355.6%). Of those who achieved CR, 27 underwent allogeneic stem cell transplantation (SCT), and 12 SCT recipients showed long-term survival. Grade 3/4 non-hematological adverse events included infection (59%), nausea/vomiting (15%), diarrhea (7%), and elevated liver enzymes (7%). In conclusion, FLAGM is an effective and safe salvage therapy for patients with relapsed/refractory AML, and facilitated SCT for a large proportion of patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12185-019-02606-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8438330", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.7534124", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5912482", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "109"
      }
    ], 
    "keywords": [
      "refractory acute myeloid leukemia", 
      "acute myeloid leukemia", 
      "stem cell transplantation", 
      "phase II study", 
      "myeloid leukemia", 
      "early death", 
      "non-hematological adverse events", 
      "Two-year overall survival", 
      "allogeneic stem cell transplantation", 
      "long-term survival", 
      "safe salvage therapy", 
      "nausea/vomiting", 
      "elevated liver enzymes", 
      "complete remission rate", 
      "efficacy of ara", 
      "FLAG regimen", 
      "salvage therapy", 
      "remission rate", 
      "primary endpoint", 
      "SCT recipients", 
      "overall survival", 
      "adverse events", 
      "poor prognosis", 
      "AML patients", 
      "cell transplantation", 
      "intracellular ara", 
      "best therapy", 
      "liver enzymes", 
      "major endpoints", 
      "patients", 
      "phase I", 
      "therapy", 
      "single case", 
      "leukemia", 
      "endpoints", 
      "efficacy", 
      "death", 
      "survival", 
      "ara", 
      "large proportion", 
      "vomiting", 
      "regimen", 
      "pneumonia", 
      "transplantation", 
      "prognosis", 
      "diarrhea", 
      "mitoxantrone", 
      "infection", 
      "recipients", 
      "study", 
      "toxicity", 
      "conclusion", 
      "investigators", 
      "group", 
      "proportion", 
      "triphosphate", 
      "cases", 
      "rate", 
      "events", 
      "enzyme", 
      "use", 
      "results", 
      "Cr", 
      "II study", 
      "FLAGM therapy", 
      "Grade 3/4 non-hematological adverse events", 
      "FLAGM"
    ], 
    "name": "Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia", 
    "pagination": "418-425", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111933579"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-019-02606-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30725360"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-019-02606-0", 
      "https://app.dimensions.ai/details/publication/pub.1111933579"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_796.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12185-019-02606-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02606-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02606-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02606-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02606-0'


 

This table displays all metadata directly associated to this object as RDF triples.

367 TRIPLES      22 PREDICATES      113 URIs      100 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-019-02606-0 schema:about N0812e126e18b4dc7b172bb09507fa582
2 N1a4a99e2a9c442a19bcddbcc023db5b3
3 N2e55a13b861a4bff8a0de2e1adb5d99b
4 N3a83eecc0af94ba8ba0c734eafb8e888
5 N4118b3254ffe43e38d9808459487dc1c
6 N48f57f0dedbc4d57ba79a59bd503e9eb
7 N5e78a1c72b584a3c8c6356f6331fda0f
8 N80aafeaef22c4629a49a5dd0aed8bd57
9 N80b41d227b5e4abab4b038947b112b2f
10 N9a1f00961f024ca291f7aa4934c86c80
11 Nc04f92b6913040bc96534b0b513d9dd5
12 Nc9f57907cc1e461d912880db4a23ea46
13 Ndf1ad99e2faa499f8275b0c6d889c375
14 Ne0ef58377ff848e2830650998c3a5358
15 Nec57bf30716f412a9557ca8f8d304715
16 anzsrc-for:11
17 anzsrc-for:1102
18 schema:author N8bd6e04bb0a44879ae96551621de83d2
19 schema:citation sg:pub.10.1007/s00277-003-0624-2
20 sg:pub.10.1007/s002770050541
21 sg:pub.10.1038/sj.leu.2401406
22 sg:pub.10.1038/sj.leu.2401568
23 sg:pub.10.1532/ijh97.07072
24 schema:datePublished 2019-02-06
25 schema:datePublishedReg 2019-02-06
26 schema:description Given the poor prognosis of patients with relapsed/refractory acute myeloid leukemia (AML), better therapy is needed. Fludarabine enhances the efficacy of Ara-C (cytarabine) by increasing intracellular Ara-C-triphosphate. The FLAG (fludarabine, high-dose Ara-C, supported with granulocyte colony-stimulating factor) regimen has been tested for use in AML patients by other investigators. In the phase II study reported here, we evaluated the efficacy and toxicity of FLAGM therapy (FLAG with mitoxantrone), further intensified by adding mitoxantrone, based on the results of a phase I study by our group. The major endpoints were complete remission (CR) rate and early death. From June 2004 to February 2008, 41 patients (median age 52 years; range 18–64 years) were enrolled. Thirty (73% 95% CI 58–84%) patients achieved CR, which met the primary endpoint; there was a single case of early death from pneumonia. Two-year overall survival was 39.4% (95% CI 25.2–55.6%). Of those who achieved CR, 27 underwent allogeneic stem cell transplantation (SCT), and 12 SCT recipients showed long-term survival. Grade 3/4 non-hematological adverse events included infection (59%), nausea/vomiting (15%), diarrhea (7%), and elevated liver enzymes (7%). In conclusion, FLAGM is an effective and safe salvage therapy for patients with relapsed/refractory AML, and facilitated SCT for a large proportion of patients.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree false
30 schema:isPartOf Nbebfa283a9a34669a622be4d4140726e
31 Nc863af519f6a4f819058860517ed9620
32 sg:journal.1076985
33 schema:keywords AML patients
34 Cr
35 FLAG regimen
36 FLAGM
37 FLAGM therapy
38 Grade 3/4 non-hematological adverse events
39 II study
40 SCT recipients
41 Two-year overall survival
42 acute myeloid leukemia
43 adverse events
44 allogeneic stem cell transplantation
45 ara
46 best therapy
47 cases
48 cell transplantation
49 complete remission rate
50 conclusion
51 death
52 diarrhea
53 early death
54 efficacy
55 efficacy of ara
56 elevated liver enzymes
57 endpoints
58 enzyme
59 events
60 group
61 infection
62 intracellular ara
63 investigators
64 large proportion
65 leukemia
66 liver enzymes
67 long-term survival
68 major endpoints
69 mitoxantrone
70 myeloid leukemia
71 nausea/vomiting
72 non-hematological adverse events
73 overall survival
74 patients
75 phase I
76 phase II study
77 pneumonia
78 poor prognosis
79 primary endpoint
80 prognosis
81 proportion
82 rate
83 recipients
84 refractory acute myeloid leukemia
85 regimen
86 remission rate
87 results
88 safe salvage therapy
89 salvage therapy
90 single case
91 stem cell transplantation
92 study
93 survival
94 therapy
95 toxicity
96 transplantation
97 triphosphate
98 use
99 vomiting
100 schema:name Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia
101 schema:pagination 418-425
102 schema:productId N02912fbdf02348ce8271192c370e5340
103 N0bd324db7b6c4083bb9378c4d0e20d9f
104 N4fa8edffc6184e41ab8065798e80d3fb
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111933579
106 https://doi.org/10.1007/s12185-019-02606-0
107 schema:sdDatePublished 2021-11-01T18:34
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher N9c7d310ba67140bda60f92cb4545c791
110 schema:url https://doi.org/10.1007/s12185-019-02606-0
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N002ba010e6c54fce993012f023b47c6d rdf:first sg:person.01114721672.90
115 rdf:rest Ndb0fc85705eb4c5ca3d3665c3601c8f2
116 N02912fbdf02348ce8271192c370e5340 schema:name pubmed_id
117 schema:value 30725360
118 rdf:type schema:PropertyValue
119 N0812e126e18b4dc7b172bb09507fa582 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Male
121 rdf:type schema:DefinedTerm
122 N0bd324db7b6c4083bb9378c4d0e20d9f schema:name dimensions_id
123 schema:value pub.1111933579
124 rdf:type schema:PropertyValue
125 N1671d08ce33049dba25aec84b5d5a282 rdf:first sg:person.01173414200.21
126 rdf:rest N50a8ce128ad14907b4ad798a31c5c7d3
127 N1a4a99e2a9c442a19bcddbcc023db5b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Humans
129 rdf:type schema:DefinedTerm
130 N2e55a13b861a4bff8a0de2e1adb5d99b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Leukemia, Myeloid, Acute
132 rdf:type schema:DefinedTerm
133 N3a83eecc0af94ba8ba0c734eafb8e888 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Cytarabine
135 rdf:type schema:DefinedTerm
136 N4118b3254ffe43e38d9808459487dc1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Vidarabine
138 rdf:type schema:DefinedTerm
139 N48f57f0dedbc4d57ba79a59bd503e9eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Survival Rate
141 rdf:type schema:DefinedTerm
142 N4934b7fa32034d5d8ed9e8beca6a9d08 rdf:first sg:person.0575627640.70
143 rdf:rest N7794f3bfd8ac4021a91c844df32b3089
144 N4d2338d021c04175972b68e662c18d21 rdf:first sg:person.0601706771.30
145 rdf:rest Ne14556a11c934bc0a4436e656b8ea7fe
146 N4fa8edffc6184e41ab8065798e80d3fb schema:name doi
147 schema:value 10.1007/s12185-019-02606-0
148 rdf:type schema:PropertyValue
149 N50a8ce128ad14907b4ad798a31c5c7d3 rdf:first sg:person.01364761132.09
150 rdf:rest N6ee88a02b9aa4eeda9c616512c02bf7c
151 N5bbacc2caeb54b9f949fd94f3a47261b schema:affiliation grid-institutes:grid.260026.0
152 schema:familyName Nishii
153 schema:givenName Kazuhiro
154 rdf:type schema:Person
155 N5d2f9b511bc94fd39bdfd6a6e7fb8087 rdf:first N756cd5d2ae5641e1bc18d767f2a59247
156 rdf:rest rdf:nil
157 N5e78a1c72b584a3c8c6356f6331fda0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Granulocyte Colony-Stimulating Factor
159 rdf:type schema:DefinedTerm
160 N6ee88a02b9aa4eeda9c616512c02bf7c rdf:first N5bbacc2caeb54b9f949fd94f3a47261b
161 rdf:rest Nb162646b2478472fab2aee43355eb4db
162 N7794f3bfd8ac4021a91c844df32b3089 rdf:first sg:person.012076005472.25
163 rdf:rest N855c18935f754af3bfacbe2121f67656
164 N7df7142ea9ee4c6d8dab90c8b57c0f3e rdf:first sg:person.01343053337.33
165 rdf:rest N8936e295ecde40deb21e24b89b3c8b6b
166 N80aafeaef22c4629a49a5dd0aed8bd57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Antineoplastic Combined Chemotherapy Protocols
168 rdf:type schema:DefinedTerm
169 N80b41d227b5e4abab4b038947b112b2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Mitoxantrone
171 rdf:type schema:DefinedTerm
172 N855c18935f754af3bfacbe2121f67656 rdf:first sg:person.01214531143.40
173 rdf:rest Nefb88fa282614ea184a152696e0df6bc
174 N8936e295ecde40deb21e24b89b3c8b6b rdf:first sg:person.0617447237.02
175 rdf:rest N5d2f9b511bc94fd39bdfd6a6e7fb8087
176 N8bd6e04bb0a44879ae96551621de83d2 rdf:first sg:person.0731776361.73
177 rdf:rest N4934b7fa32034d5d8ed9e8beca6a9d08
178 N9a1f00961f024ca291f7aa4934c86c80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Female
180 rdf:type schema:DefinedTerm
181 N9c7d310ba67140bda60f92cb4545c791 schema:name Springer Nature - SN SciGraph project
182 rdf:type schema:Organization
183 Nb162646b2478472fab2aee43355eb4db rdf:first sg:person.016200371441.82
184 rdf:rest N7df7142ea9ee4c6d8dab90c8b57c0f3e
185 Nbebfa283a9a34669a622be4d4140726e schema:issueNumber 4
186 rdf:type schema:PublicationIssue
187 Nc04f92b6913040bc96534b0b513d9dd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Adult
189 rdf:type schema:DefinedTerm
190 Nc863af519f6a4f819058860517ed9620 schema:volumeNumber 109
191 rdf:type schema:PublicationVolume
192 Nc9f57907cc1e461d912880db4a23ea46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Middle Aged
194 rdf:type schema:DefinedTerm
195 Ndb0fc85705eb4c5ca3d3665c3601c8f2 rdf:first sg:person.0716044066.58
196 rdf:rest N4d2338d021c04175972b68e662c18d21
197 Ndf1ad99e2faa499f8275b0c6d889c375 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Disease-Free Survival
199 rdf:type schema:DefinedTerm
200 Ne0ef58377ff848e2830650998c3a5358 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Adolescent
202 rdf:type schema:DefinedTerm
203 Ne14556a11c934bc0a4436e656b8ea7fe rdf:first sg:person.01103067640.12
204 rdf:rest Nf870ca99b2ea4095a7dd44728c0b3fe4
205 Nec57bf30716f412a9557ca8f8d304715 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Recurrence
207 rdf:type schema:DefinedTerm
208 Nefb88fa282614ea184a152696e0df6bc rdf:first sg:person.0763374015.04
209 rdf:rest N002ba010e6c54fce993012f023b47c6d
210 Nf870ca99b2ea4095a7dd44728c0b3fe4 rdf:first sg:person.0603027536.70
211 rdf:rest N1671d08ce33049dba25aec84b5d5a282
212 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
213 schema:name Medical and Health Sciences
214 rdf:type schema:DefinedTerm
215 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
216 schema:name Cardiorespiratory Medicine and Haematology
217 rdf:type schema:DefinedTerm
218 sg:grant.5912482 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-019-02606-0
219 rdf:type schema:MonetaryGrant
220 sg:grant.7534124 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-019-02606-0
221 rdf:type schema:MonetaryGrant
222 sg:grant.8438330 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-019-02606-0
223 rdf:type schema:MonetaryGrant
224 sg:journal.1076985 schema:issn 0925-5710
225 1865-3774
226 schema:name International Journal of Hematology
227 schema:publisher Springer Nature
228 rdf:type schema:Periodical
229 sg:person.01103067640.12 schema:affiliation grid-institutes:grid.410814.8
230 schema:familyName Morii
231 schema:givenName Takeshi
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103067640.12
233 rdf:type schema:Person
234 sg:person.01114721672.90 schema:affiliation grid-institutes:grid.411898.d
235 schema:familyName Usui
236 schema:givenName Noriko
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114721672.90
238 rdf:type schema:Person
239 sg:person.01173414200.21 schema:affiliation grid-institutes:grid.415067.1
240 schema:familyName Ogura
241 schema:givenName Michinori
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173414200.21
243 rdf:type schema:Person
244 sg:person.012076005472.25 schema:affiliation grid-institutes:grid.163577.1
245 schema:familyName Yamauchi
246 schema:givenName Takahiro
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012076005472.25
248 rdf:type schema:Person
249 sg:person.01214531143.40 schema:affiliation grid-institutes:grid.505613.4
250 schema:familyName Takeshita
251 schema:givenName Akihiro
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214531143.40
253 rdf:type schema:Person
254 sg:person.01343053337.33 schema:affiliation grid-institutes:grid.505613.4
255 schema:familyName Ohnishi
256 schema:givenName Kazunori
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343053337.33
258 rdf:type schema:Person
259 sg:person.01364761132.09 schema:affiliation grid-institutes:grid.265061.6
260 schema:familyName Machida
261 schema:givenName Shinichiro
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364761132.09
263 rdf:type schema:Person
264 sg:person.016200371441.82 schema:affiliation grid-institutes:grid.174567.6
265 schema:familyName Honda
266 schema:givenName Sumihisa
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016200371441.82
268 rdf:type schema:Person
269 sg:person.0575627640.70 schema:affiliation grid-institutes:grid.410806.b
270 schema:familyName Miyawaki
271 schema:givenName Shuichi
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575627640.70
273 rdf:type schema:Person
274 sg:person.0601706771.30 schema:affiliation grid-institutes:grid.263518.b
275 schema:familyName Ishida
276 schema:givenName Fumihiro
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601706771.30
278 rdf:type schema:Person
279 sg:person.0603027536.70 schema:affiliation grid-institutes:grid.420115.3
280 schema:familyName Kano
281 schema:givenName Yasuhiko
282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603027536.70
283 rdf:type schema:Person
284 sg:person.0617447237.02 schema:affiliation grid-institutes:grid.27476.30
285 schema:familyName Naoe
286 schema:givenName Tomoki
287 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617447237.02
288 rdf:type schema:Person
289 sg:person.0716044066.58 schema:affiliation grid-institutes:grid.412039.d
290 schema:familyName Arai
291 schema:givenName Yukihiro
292 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716044066.58
293 rdf:type schema:Person
294 sg:person.0731776361.73 schema:affiliation grid-institutes:grid.416616.2
295 schema:familyName Hatsumi
296 schema:givenName Nahoko
297 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731776361.73
298 rdf:type schema:Person
299 sg:person.0763374015.04 schema:affiliation grid-institutes:grid.410804.9
300 schema:familyName Komatsu
301 schema:givenName Norio
302 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763374015.04
303 rdf:type schema:Person
304 sg:pub.10.1007/s00277-003-0624-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075273463
305 https://doi.org/10.1007/s00277-003-0624-2
306 rdf:type schema:CreativeWork
307 sg:pub.10.1007/s002770050541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050548097
308 https://doi.org/10.1007/s002770050541
309 rdf:type schema:CreativeWork
310 sg:pub.10.1038/sj.leu.2401406 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023213497
311 https://doi.org/10.1038/sj.leu.2401406
312 rdf:type schema:CreativeWork
313 sg:pub.10.1038/sj.leu.2401568 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036106851
314 https://doi.org/10.1038/sj.leu.2401568
315 rdf:type schema:CreativeWork
316 sg:pub.10.1532/ijh97.07072 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015720903
317 https://doi.org/10.1532/ijh97.07072
318 rdf:type schema:CreativeWork
319 grid-institutes:grid.163577.1 schema:alternateName First Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
320 schema:name First Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
321 rdf:type schema:Organization
322 grid-institutes:grid.174567.6 schema:alternateName Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
323 schema:name Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
324 rdf:type schema:Organization
325 grid-institutes:grid.260026.0 schema:alternateName Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
326 schema:name Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
327 rdf:type schema:Organization
328 grid-institutes:grid.263518.b schema:alternateName Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
329 schema:name Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
330 rdf:type schema:Organization
331 grid-institutes:grid.265061.6 schema:alternateName Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
332 schema:name Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
333 rdf:type schema:Organization
334 grid-institutes:grid.27476.30 schema:alternateName Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
335 schema:name Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
336 rdf:type schema:Organization
337 grid-institutes:grid.410804.9 schema:alternateName Division of Hematology, Jichi Medical University, Shimotsuke, Japan
338 schema:name Division of Hematology, Jichi Medical University, Shimotsuke, Japan
339 rdf:type schema:Organization
340 grid-institutes:grid.410806.b schema:alternateName Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka Toshima-ku, 170-8476, Tokyo, Japan
341 schema:name Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka Toshima-ku, 170-8476, Tokyo, Japan
342 Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan
343 rdf:type schema:Organization
344 grid-institutes:grid.410814.8 schema:alternateName The Second Department of Internal Medicine, Nara Medical University, Nara, Japan
345 schema:name The Second Department of Internal Medicine, Nara Medical University, Nara, Japan
346 rdf:type schema:Organization
347 grid-institutes:grid.411898.d schema:alternateName Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
348 schema:name Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
349 rdf:type schema:Organization
350 grid-institutes:grid.412039.d schema:alternateName Department of Hematology, Dokkyo University School of Medicine, Mibu, Japan
351 schema:name Department of Hematology, Dokkyo University School of Medicine, Mibu, Japan
352 rdf:type schema:Organization
353 grid-institutes:grid.415067.1 schema:alternateName Department of Hematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan
354 schema:name Department of Hematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan
355 Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan
356 rdf:type schema:Organization
357 grid-institutes:grid.416616.2 schema:alternateName Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan
358 schema:name Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan
359 rdf:type schema:Organization
360 grid-institutes:grid.420115.3 schema:alternateName Division of Hematology, Tochigi Cancer Center, Utsunomiya, Japan
361 schema:name Division of Hematology, Tochigi Cancer Center, Utsunomiya, Japan
362 rdf:type schema:Organization
363 grid-institutes:grid.505613.4 schema:alternateName Department of Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan
364 Oncology Center, Hamamatsu University School of Medicine, Hamamatsu, Japan
365 schema:name Department of Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan
366 Oncology Center, Hamamatsu University School of Medicine, Hamamatsu, Japan
367 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...